Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients – focus on esomeprazole

Raymond SY Tang
Justin CY Wu
Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong

Abstract: Peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are not uncommon in elderly patients. Clinical presentations of these acid-related disorders may be atypical in the geriatric population. Older individuals are at increased risk for poor outcomes in complicated PUD and for development of GERD complications. Multiple risk factors (eg, *Helicobacter pylori* [HP], use of nonsteroidal anti-inflammatory drugs [NSAIDs], aspirin) contribute to the development of PUD. Recent data has shown that HP-negative, NSAID-negative idiopathic peptic ulcers are on the rise and carry a higher risk of recurrent ulcer bleeding and mortality. Effective management of PUD in the geriatric population relies on identification and modification of treatable risk factors. Elderly patients with GERD often require long-term acid suppressive therapy. Proton pump inhibitors (PPI) including esomeprazole are effective in the treatment of reflux esophagitis, maintenance of GERD symptomatic control, and management of PUD as well as its complications. Potential safety concerns of long-term PPI use have been reported in the literature. Clinicians should balance the risks and benefits before committing elderly patients to long-term PPI therapy.

Keywords: elderly patients, peptic ulcer disease, gastroesophageal reflux disease, proton pump inhibitor, esomeprazole

Introduction

Peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are both common acid-related disorders. Management of acid-related disorders in the elderly patient population represents a unique challenge as the epidemiology, clinical presentations, and outcomes may be different from their younger counterparts.1,2 There is also a higher tendency for older individuals to have multiple medical comorbidities (eg, cardiovascular disease, cerebral vascular disease, diabetes, chronic kidney disease, degenerative joint disease) requiring them to use medications (eg, aspirin, nonsteroidal anti-inflammatory drugs [NSAIDs]) that increase the risk of upper gastrointestinal (GI) injury. Although acid suppressive therapy has become the cornerstone in the management of PUD and GERD, the safety and tolerability of various acid suppressive agents deserve special attention in the geriatric population. This article aims to review the key issues in the management of PUD and GERD in elderly Chinese patients and the use of proton pump inhibitors (PPI) in acid-related disorders with a focus on esomeprazole.

PUD

Epidemiology and risk factors

Although the incidence of uncomplicated PUD has decreased in recent years in the general population, elderly patients remain at high risk for PUD and its complications such as bleeding or perforation.3–5
Old age and the presence of comorbidities have been consistently shown to be risk factors for poor outcomes in patients with complicated PUD.5-9 In a large population-based study of 7,232 patients with bleeding peptic ulcer, the standardized 30-day mortality among patients older than 80 years was 16.9% compared with 4.3% among patients younger than 65 years.6 Another study reported a higher annual incidence of perforation in PUD patients who were greater than 65 years old.7 In a population-based study including patients with peptic ulcer bleeding and perforation, diabetes was associated with increased short-term mortality.8 In a retrospective review of 9,375 Chinese patients with peptic ulcer bleeding in a tertiary center, 577 patients died, with a majority of them (79.7%) dying of non-bleeding related causes (eg, multiorgan failure, pulmonary conditions, and terminal malignancy).9 This has significant implications in the elderly population with PUD as they often have cardiovascular, pulmonary, metabolic, or renal comorbidities.

Helicobacter pylori (HP) infection, the use of NSAIDs, and the use of aspirin and/or other antithrombotic drugs are important risk factors for PUD and its complications in the geriatric population.4,10 However in the last decade, there is also emerging evidence to suggest that the incidence of HP-negative, NSAID-negative, idiopathic peptic ulcers is on the rise.11 Elderly patients may be at higher risk for the HP-negative, NSAID-negative ulcers as reduction in gastric or duodenal mucosal barriers often occurs with aging.1

Clinical presentations
Manifestations of PUD in elderly patients may be atypical. In a prospective study with 277 patients with PUD, two-thirds of the patients aged more than 60 years reported vague abdominal pain as the main symptom.12 Nonspecific symptoms of PUD often lead to delayed diagnosis and development of PUD complications in the geriatric population.1

Management of HP related ulcers
In a study focusing on elderly peptic ulcer patients, 70% of the elderly patients were found to be HP positive.4 A meta-analysis of epidemiologic studies conducted in a Mainland Chinese population reported a HP infection rate of 58%.13 In a recent population-based study from Shanghai, People’s Republic of China, PUD was found in 17.2% of the 1,022 analyzed patients and HP infection was found in 92.6% of patients with PUD.14 With a population of 1.3 billion in Mainland China, the burden of HP infection and its related complications is significant. Untreated HP-associated peptic ulcers tend to recur.15 Hence, it is important to test and treat HP infection in elderly patients who present with PUD.

Treatment of HP in elderly patients is similar to that in their younger counterparts, but attention should be given to the local antibiotic resistance of the HP strains, as well as the compliance and tolerability of the regimens in the elderly patients. Management guidelines from the Maastricht III Consensus Report and the American College of Gastroenterology in 2007 recommend first-line treatment of HP infection with clarithromycin-based triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) for 7 to 14 days or bismuth-based quadruple therapy (PPI, bismuth, metronidazole, and tetracycline) for 10 to 14 days.16,17 Unfortunately, HP treatment eradication rates are far from ideal in these established regimens. Major clinical studies reported intention-to-treat HP eradication rates of only 70% to 80% regarding these regimens.18,19 Data from meta-analyses regarding first-line triple therapy for HP showed that increasing the duration of triple therapy from 7 days to 14 days increased the eradication rate by 5% to 9%.20,21

The prevalence of antibiotic resistance in HP must be taken into consideration when choosing among the various eradication regimens to maximize the chance of success. The rise in clarithromycin resistance may explain the high failure rate of clarithromycin-based regimens in some studies.22 On the other hand, metronidazole resistance may be more relative, and can sometimes be overcome by using a higher dose of metronidazole or using it in a quadruple regimen with PPI, bismuth, and tetracycline.23 In areas with high clarithromycin and metronidazole resistance, bismuth-based quadruple therapy should be used for first-line therapy.16,17 Salvage regimens containing levofloxacin or rifabutin can be considered, if a patient fails regimens containing clarithromycin and metronidazole.16,17 Recently, four-drug regimens (concomitant or sequential) besides the bismuth-based quadruple regimen have been studied and may be alternatives to traditional triple therapy in regions with suboptimal HP eradication rates.24,25

Since HP eradication regimens involve multiple antibiotics, monitoring for compliance and potential drug interactions with patients’ routine medications are particularly important in the geriatric population. When elderly patients have persistent HP infection, the possibility of noncompliance should be explored.

Management of NSAID related ulcers
Elderly patients often develop degenerative joint diseases during the aging process. NSAIDs, which are often prescribed
for pain relief, have emerged as one of the most important causes of recurrent peptic ulcer disease and its complications in many developed countries as the incidence of HP-associated ulcers decline. Up to 25% of chronic NSAID users develop ulcer disease, of which 2% to 4% will have complications such as bleeding or perforation.\textsuperscript{26,27}

Multiple risk factors for NSAID-related GI complications have been described, including advanced age, a prior GI event, high-dose NSAID therapy, concomitant use of low-dose aspirin, anticoagulants, or corticosteroids, and cardiovascular diseases.\textsuperscript{27,28} Mixed results have been reported regarding HP infection in ulcer risk of NSAID users.\textsuperscript{37} Nevertheless, HP infection likely increases the risk of NSAID related GI complications given data from a randomized study showing that HP eradication significantly reduces the risk of ulcers for patients on NSAIDs.\textsuperscript{29}

Ideally, the best preventive strategy is to avoid NSAIDs entirely in patients with history of NSAID related ulcers or complications. However, NSAIDs are often prescribed in elderly patients with chronic joint pain, placing them at higher risk for PUD. Thus co-therapy with a gastroprotective agent is desirable. Systematic reviews of multiple randomized controlled studies have shown that PPI, misoprostol, and double-dose histamine-2-receptor antagonist (H2RA) are effective at preventing chronic NSAID related endoscopic gastric and duodenal ulcers.\textsuperscript{30–32}

Until recently, substitution of cyclooxygenase-2 (COX-2) selective NSAIDs for nonselective NSAIDs in patients at risk for GI injury has been a popular option. However, emerging data on cardiovascular risks of COX-2 inhibitors and other nonselective NSAIDs have raised concerns about their use. Data from systematic reviews of observational studies and randomized trials showed that both COX-2 inhibitors and nonselective NSAIDs are associated with increased cardiothrombotic risk, with the probable exception of naproxen.\textsuperscript{33,34} Elderly patients may be particularly affected as they often have underlying ischemic heart disease or diabetes, putting them at higher risk for cardiovascular thrombotic events. For patients who require chronic NSAID use, the patient’s cardiovascular risk will affect the initial choice of NSAID (eg, naproxen versus others), and the patient’s GI risk factors will dictate the type of GI protection strategy (see Table 1).\textsuperscript{27}

### Management of peptic ulcers in patients on aspirin and/or other antithrombotic drugs

Cardiovascular and cerebral vascular diseases are not uncommon in the geriatric population. These patients are usually on long-term aspirin and/or other antithrombotic drug therapy, placing them at high risk for GI complications. Indeed, low-dose aspirin has emerged as one of the most important causes of peptic ulcer bleeding in developed countries. Advanced age (>70 years of age), prior history of ulcer bleeding, dose of aspirin, concomitant use of NSAIDs, and HP infection have been consistently shown to be risk factors for upper GI bleeding in aspirin users.\textsuperscript{35,36} In a recent study of high risk myocardial infarction survivors on aspirin, additional risk factors for GI bleeding, including use of dual antiplatelet therapy, concomitant anticoagulants, history of alcohol abuse, New York Heart Association class III or IV, diabetes, renal failure, male sex, and non-white race have been identified.\textsuperscript{37} The abovementioned risk factors are relevant to elderly patients since many of them would have more than one of the risk factors.

The main strategies for reducing upper GI bleeding in aspirin users focus on elimination of risk factors and co-therapy with a gastroprotective agent. In a randomized trial comparing HP eradication therapy alone to maintenance treatment with a PPI in aspirin users with HP infection and prior ulcer bleeding in Hong Kong, recurrent ulcer bleeding occurred in 1.9% of patients in the HP eradication therapy group and in 0.9% of the PPI group.\textsuperscript{38} In another recently published prospective cohort study of three cohorts of aspirin users in Hong Kong (HP-eradicated cohort, HP-negative

| **Table 1** Ulcer prevention strategy according to cardiovascular and gastrointestinal risks in patients on chronic NSAID therapy |
|----------------------------------|-----------------|------------------------|
| **GI risk**                      | Low\textsuperscript{a} | Moderate\textsuperscript{b} | High\textsuperscript{c} |
| CV risk: low                     | Nonselective NSAID | NSAID and PPI or misoprostol, or COX-2 inhibitor alone | COX-2 inhibitor and PPI or misoprostol |
| (low-dose aspirin not needed)    |                 |                        |                          |
| CV risk: high                    | Naproxen and PPI or misoprostol | Naproxen and PPI or misoprostol | Avoid NSAID and COX-2 inhibitor if possible |
| (low-dose aspirin needed)        |                 |                        |                          |

**Notes:** GI risk factors: age >65 years, high-dose NSAID therapy, previous history of peptic ulcer, concomitant use of aspirin, corticosteroids, or anticoagulants. \textsuperscript{a}Low GI risk = no GI risk factor; \textsuperscript{b}moderate GI risk = one to two GI risk factors (eg, prior uncomplicated peptic ulcer); \textsuperscript{c}high GI risk = more than two GI risk factors or prior complicated peptic ulcer. Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738, copyright 2009.\textsuperscript{27}

**Abbreviations:** COX-2 inhibitor, cyclooxygenase-2 inhibitor; CV, cardiovascular; GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor.
Tang and Wu

Dovepress

Management of HP-negative, NSAID-negative ulcers

Emerging data has suggested that the proportion of HP-negative, NSAID-negative idiopathic peptic ulcers appears to be on the rise. Because reductions in gastric and duodenal barriers often occur in the aging process, elderly patients are at higher risk for HP-negative, NSAID-negative ulcers. For patients with both high bleeding and thrombotic risks, staggered administration (12 hours apart) of PPI and clopidogrel can be considered, with avoidance of omeprazole as choice of PPI. Alternate antiplatelet regimens should be considered.51

Dual antiplatelet therapy (eg, aspirin and clopidogrel) has been increasingly used in patients with coronary artery stents. Randomized studies have shown an increased risk of major GI bleeding in patients receiving dual antiplatelet therapy for acute coronary syndrome or atrial fibrillation.53-54 The updated joint consensus report in 2008 by the American College of Cardiology Foundation, American College of Gastroenterology, and American Heart Association recommended routine prophylactic PPI use in patients on dual antiplatelet therapy.42 Subsequently, results from a randomized trial confirmed the efficacy of prophylactic PPI in reducing upper GI bleeding associated with dual antiplatelet therapy.45 However, concerns do exist in the use of PPI co-therapy. Recently, based on findings from in vitro studies and observational studies, there have been concerns about potentially unfavorable interaction between PPI and clopidogrel.55-57 A significant increase in the risk of myocardial infarction in patients receiving concomitant PPI was found in a meta-analysis of cardiovascular outcomes in patients receiving clopidogrel with or without PPI.49 However, on subgroup analysis, data from randomized trials or propensity-matched participants did not show such association.49 To date, data from the only double-blinded randomized trial designed to address whether concomitant use of PPI with clopidogrel would adversely affect cardiovascular outcome did not find apparent cardiovascular interaction between clopidogrel and omeprazole.45 For patients on dual antiplatelet therapy, strategies to prevent recurrent PUD and its complications center on balancing the bleeding and thrombotic risks of individual patients.50,51 For patients with high bleeding risk and low thrombotic risk patients, PPI prophylaxis with standard dual antiplatelet therapy can be considered.51 For patients with both high bleeding and...
gastroprotective agents may be preferentially prescribed to older and sicker patients in this cohort. Further research will be needed to better define the optimal long-term management strategy for patients with HP-negative, NSAID-negative idiopathic ulcers.

**GERD**

**Epidemiology and risk factors**

GERD is a chronic relapsing peptic disorder characterized by recurrent acid reflux symptoms and/or extra-esophageal manifestations.59 Although GERD is a common GI complaint, it is frequently undiagnosed and undertreated in elderly patients.2 While the prevalence of GERD is about 10%–20% in Western countries, the majority of the Asian epidemiologic studies have reported a lower prevalence of less than 10%.56–58 Dedicated studies of GERD in elderly patients are limited. Based on data from studies of elderly patients in the USA, the incidence of symptomatic GERD was reported to range from 14%–20% and did not appear to increase with age.59,60 On the other hand, GERD complications such as esophagitis, stricture, and Barrett’s esophagus were reported to be more common in older people. In a USA study, significantly more cases of erosive esophagitis and Barrett’s esophagus were diagnosed in patients aged 60 years or above (81%) when compared to younger patients (47%).61 In another study of 194,527 patients from the hospitals of the Department of Veteran Affairs in the USA, older age, male sex, and white ethnicity were reported to be risk factors in the development of severe forms of GERD including esophageal erosions, ulcers, or strictures.62 Although impaired esophageal barriers to acid reflux may occur due to aging, the cumulative injury of acid to the esophageal mucosa for a prolonged period may be the reason for the increased severity of GERD in elderly patients.2 Risk factors for GERD in Asian patients appear to be similar to those reported in Western populations, with male sex, smoking, high-fat diet, obesity, stress, and major life events being the most consistent ones.56

**Pathophysiology**

Multiple mechanisms such as transient lower esophageal sphincter relaxation (TLESR) with excessive acid reflux, hiatus hernia, impaired esophageal peristalsis, and weak lower esophageal sphincter (LES) contribute to the development of GERD.2,56 TLESR with excessive acid reflux has been shown to be the most important mechanism.2,56 In elderly patients, age itself does not appear to cause decrease in LES pressure.2 Rather, geriatric patients often take medications known to reduce LES pressure (eg, nitrates, calcium channel blockers, benzodiazepines, anticholinergics, antidepressants).2 The prevalence of hiatus hernia was reported to increase with age.63 When compared to a Western population, the prevalence of hiatus hernia was found to be lower in Asian populations.64

In both Western and Asian populations, obesity has been shown to have a strong association with GERD.55,66 In a recent study from Hong Kong, body mass index and waist circumference were shown to correlate with TLESR and gastroesophageal pressure gradient in GERD patients.56 The rise in prevalence of GERD in Asian populations may be related to the increase in obesity.56

There has been controversy in the role of HP in GERD between Western and Asian studies. A negative association between HP infection and GERD was reported in many Asian studies.56,67 HP infection in GERD patients was reported to be lower than in those without reflux symptoms in Asia, with prevalence ranging from 25% to 35%.56,68,69 In HP infected patients with corpus gastritis and atrophic gastritis, eradication of HP was found to be associated with recovery of gastric acid secretion and development of reflux esophagitis.70 In GERD patients infected with HP, any protective effect of HP infection may be offset by the presence of more severe LES dysfunction and esophageal dysmotility.71

**Clinical presentations**

Elderly patients with GERD tend to present less frequently with typical GERD symptoms such as heartburn or acid regurgitation.2,72 In GERD patients aged 65 years or older, other symptoms such as weight loss, anorexia, dysphagia, or vomiting were reported to increase with age.72,73 GERD complications such as esophagitis, strictures, or Barrett’s esophagus have been reported to be more common in older individuals.2 In Asian populations, chest pain and atypical esophageal symptoms were reported to be common presenting symptoms of GERD.56 A study of Chinese patients with noncardiac chest pain reported that symptomatic response to PPI predicts abnormal acid reflux in patients without esophagitis.74

**Management**

GERD runs a chronic relapsing course and long-term therapy is needed for the majority of patients. Although treatment principles in elderly GERD patients are similar to those of younger adult patients, clinicians should be reminded that older individuals are more likely to have esophagitis or other GERD complications that often require more aggressive treatment.2,72 While lifestyle modifications, antacids,
algic acid, and H2RA are helpful in the management of milder GERD symptoms, PPI is the standard therapy for GERD patients who require long-term symptomatic relief or develop complications such as erosive esophagitis, strictures, and Barrett’s esophagus. PPI has been shown to be effective in providing symptomatic relief of GERD and healing of esophagitis in different age groups. As geriatric patients often require long-term PPI therapy for symptomatic relief or treatment of GERD complications, the benefits and potential risks of chronic PPI use will be further discussed below.

**Use of PPIs in acid-related disorders – with a focus on esomeprazole**

PPIs play a major role in the current management of acid-related disorders including PUD and GERD. PPIs reduce gastric acid secretion by inhibiting the proton pump (H+/K+-ATPase) in the gastric parietal cells. Omeprazole is the first PPI developed for clinical use. Esomeprazole, which is the (S)-isomer of omeprazole, is the first PPI to be developed as an optical isomer with the goal of improving the pharmacokinetics and the acid suppression characteristics of omeprazole. Esomeprazole is highly protein-bound in plasma and has a high chiral stability with a very low inversion rate to the R-isomer at 0.4%. Because esomeprazole absorption is delayed and decreased when administered before a high fat meal, it is generally advised to be taken 30 minutes to 1 hour before meals. When compared to omeprazole, a higher area under the plasma drug concentration versus time curve is achieved by esomeprazole through decreased first-pass metabolism and systemic clearance. Esomeprazole is metabolized by two cytochrome P450 isoenzymes, CYP2C19 and CYP3A4, with CYP2C19 being the major metabolic pathway. Dosing adjustment of esomeprazole is not required in elderly patients, patients with renal impairment, or mild hepatic impairment. However, dosing should be reduced in patients with severe liver dysfunction.

**Healing of reflux esophagitis**

The efficacy of esomeprazole in healing reflux esophagitis was evaluated in multiple randomized clinical trials. Healing rates of esophagitis by esomeprazole were shown to be either equivalent or statistically higher at 4 weeks when compared with omeprazole, lansoprazole, and pantoprazole. The esophagitis healing rate at 8 weeks is up to 96%.

**Maintenance of healing of esophagitis**

Esomeprazole is effective in the maintenance of the healing of reflux esophagitis. In a 12-month noncomparative study, esomeprazole at 40 mg daily was shown to maintain the healing of esophagitis in 89.4% of patients at 12 months. When compared to lansoprazole and pantoprazole, esomeprazole keeps a significantly higher proportion of patients with healed esophagitis in remission.

**Symptomatic control of GERD without esophagitis**

Esomeprazole at 20 mg or 40 mg per day for 4 weeks has been shown to provide effective symptomatic control in patients without esophagitis when compared to placebo or omeprazole. In a systemic review of 17 studies, on-demand esomeprazole and other PPIs are effective in long-term management of GERD without esophagitis.

**Use of esomeprazole in PUD**

The efficacy of esomeprazole has been demonstrated in HP eradication therapy, healing of NSAID or aspirin related peptic ulcers, and reduction of early recurrent bleeding in peptic ulcers after successful endoscopic therapy. In PPI-based triple therapy regimens utilizing esomeprazole 20 mg twice daily or 40 mg daily for HP eradication, a 7-day regimen with esomeprazole 20 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily achieved intention-to-treat eradication rates of 86%–90% and per protocol eradication rates of 90%–91% in duodenal ulcer patients in Canada and Europe, while a 10-day regimen with esomeprazole 40 mg daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily achieved intention-to-treat eradication rates of 77%–78% and per protocol eradication rates of 84%–85% in duodenal ulcer patients in the USA. In patients receiving an NSAID or COX-2 inhibitor with gastric ulcer, esomeprazole (20 mg daily or 40 mg daily) resulted in a significantly higher ulcer-healing rate (88.4% and 91.5%, respectively) when compared to ranitidine 150 mg twice daily. Esomeprazole was also demonstrated to be effective in preventing the development of ulcers in long-term users of NSAIDs and COX-2 inhibitors in two large randomized trials. In HP-negative patients on long-term low-dose aspirin, esomeprazole significantly reduces the development of peptic ulcers when compared to placebo. High-dose intravenous esomeprazole after successful endoscopic hemostasis was shown to reduce recurrent peptic ulcer bleeding at 72 hours with sustained benefits up to 30 days in a multicenter randomized trial.
Safety and tolerability

Esomeprazole, as with other PPIs, is generally well-tolerated, with common side effects such as diarrhea, nausea, abdominal pain, flatulence, or headache occurring in less than 5% of patients.\(^7\) As elderly patients with acid-related disorders often require long-term PPI therapy, safety of chronic PPI use in this population deserves special attention.

Chronic PPI use may interfere with calcium absorption due to hypochlorhydria, but may also reduce bone resorption through inhibition of osteoclastic activity.\(^101,102\) Increasing clinical evidence has shown a positive association of chronic PPI use with fractures. A large nested case-control study suggested that long-term PPI use >1 year is associated with increased risk of hip fractures in patients >50 years old.\(^103\) The strength of association increases with longer duration of PPI therapy and high-dose PPI use.\(^103\) A recent meta-analysis of eleven observational studies reported increased risk of hip, wrist, and spine fractures in chronic PPI users.\(^104\) Thus, in elderly patients with other risk factors for fractures (eg, osteoporosis, prior fractures), long-term (>1 year) high-dose PPI should be avoided. Calcium and vitamin D supplements may be considered in high risk patients.

Increased risk of certain infections (eg, enteric infections, spontaneous bacterial peritonitis in cirrhotic patients, and respiratory infections) has been reported with PPI use.\(^105-116\) A large population-based case-control study suggested an increased risk of *Campylobacter* and *Salmonella* gastroenteritis in PPI users, but not in H2RA users.\(^105\) Growing evidence based on initial population-based case-control studies and three recent meta-analyses of observational studies suggest that PPI use is associated with an increased risk of *Clostridium difficile* infection and associated diarrhea.\(^106-109\) The association was noted to be greater in PPI users than in H2RA users.\(^108\) Strategies to minimize the risk of *C. difficile* infection in the elderly population would include avoidance of high-dose PPI or temporary withdrawal of PPI in high-risk patients (eg, patients with chronic kidney disease, inflammatory bowel disease, malignancy, or immunosuppression).

In cirrhotic patients with ascites, initial retrospective case-control studies have yielded inconsistent results on the risk of spontaneous bacterial peritonitis and PPI use, but a subsequent meta-analysis reported a positive association between PPI use and increased risks of spontaneous bacterial peritonitis.\(^110-115\) Hence, PPI should be used judiciously with clearly justified indication in this group of patients.

Observational studies have suggested a possible association between PPI use and increased risk of community acquired pneumonia (CAP).\(^113-115\) The reported association remains controversial since the increased risk of CAP was mostly noted in patients with recent initiation of PPI, but not in patients with prolonged PPI use.\(^114,115\) The observed associations between recent initiation of PPI and the increased risk of CAP may be confounded.\(^116\)

Malabsorptions of certain nutrients and medications have been described in chronic PPI users. Chronic PPI use, but not past or short-term use, has been reported to be associated with vitamin B12 deficiency.\(^117-119\) Since older individuals with malnourishment are at higher risk for vitamin B12 deficiency, monitoring of B12 level should be considered in these high-risk patients on long-term PPI therapy. Hypomagnesemia in long-term PPI users due to reduced intestinal magnesium absorption has been reported.\(^120,121\) This has implications in geriatric populations since elderly patients are often taking other medications that may predispose them to hypomagnesemia (eg, digoxin or diuretics). Checking of magnesium level before and during chronic PPI therapy should be considered. Absorption of certain medications often requires an optimal gastric acidity. Malabsorption of thyroxine has been described in patients treated with acid suppressive drugs.\(^122\) In patients on thyroxine therapy, a need for a higher dose of thyroxine was observed in patients on PPI therapy.\(^122\)

The safety of chronic PPI use in HP-infected patients remains a subject of debate. It has been suggested that HP-infected patients on chronic PPI therapy have a propensity to develop atrophic gastritis, placing them at risk for gastric malignancy.\(^123\) Progression of atrophic gastritis can be prevented by eradication of HP.\(^124\) In Asian countries where the prevalence of HP infection is high, HP eradication before starting long-term PPI in GERD patients should be considered.\(^125\)

The potential unfavorable interaction between PPI and clopidogrel has been discussed previously in the PUD section of this article. In vitro studies reported that some PPIs may reduce the antiplatelet activity of clopidogrel by inhibiting the cytochrome P450 enzyme, CYP2C19.\(^46,47\) However, whether in vitro findings have good correlation with actual clinical outcomes remains controversial. In the only randomized trial designed to address the cardiovascular outcomes in patients treated with both clopidogrel and PPI, PPI use did not seem to negatively impact the cardiovascular outcomes.\(^43\) In a recent randomized trial designed to study the effects of four different PPIs (omeprazole, esomeprazole, lansoprazole, and dexlansoprazole) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel, all four PPIs were shown to reduce the active metabolite of clopidogrel.\(^126\)
Potential risks

- Risk of enteric infections (eg, Clostridium difficile)
- Risk of community-acquired pneumonia
- Risk of malabsorption of nutrients (eg, vitamin B12, magnesium, calcium, iron)
- Risk of malabsorption of certain medications (eg, thyroxine)
- Risk of atrophic gastritis in Helicobacter pylori-infected GERD patients
- Risk of unfavorable interaction between certain PPIs and clopidogrel

**Table 2** Balancing the benefits and risks of long-term proton pump inhibitor use in elderly patients

<table>
<thead>
<tr>
<th>Benefits</th>
<th>Potential risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Part of Helicobacter pylori eradication therapy</td>
<td>• Risk of enteric infections (eg, Clostridium difficile)</td>
</tr>
<tr>
<td>• Healing of peptic ulcer</td>
<td>• Risk of community-acquired pneumonia</td>
</tr>
<tr>
<td>• Co-therapy for chronic NSAID user with GI risk factors</td>
<td>• Risk of malabsorption of nutrients (eg, vitamin B12, magnesium, calcium, iron)</td>
</tr>
<tr>
<td>• Co-therapy for chronic aspirin user with prior complicated PUD</td>
<td>• Risk of malabsorption of certain medications (eg, thyroxine)</td>
</tr>
<tr>
<td>• Symptomatic control for GERD</td>
<td>• Risk of atrophic gastritis in Helicobacter pylori-infected GERD patients</td>
</tr>
<tr>
<td>• Therapy for complicated GERD (eg, reflux esophagitis, peptic stricture, Barrett's esophagus)</td>
<td>• Risk of unfavorable interaction between certain PPIs and clopidogrel</td>
</tr>
</tbody>
</table>

Omeprazole and esomeprazole were shown to significantly reduce the vasodilator-stimulated phosphoprotein platelet reactivity index, and with a stronger inhibitory effect when compared to lansoprazole and dexlansoprazole. Avoidance of concomitant use of omeprazole or esomeprazole with clopidogrel has been recommended by the United States Food and Drug Administration and the European Medicines Agency.

**Conclusion**

Acid-related disorders, including PUD and GERD, are common and often present with atypical symptoms in elderly patients. Poorer clinical outcomes in PUD and increased incidence of GERD complications are frequently observed in older individuals. Being the cornerstone in acid-suppressive therapy, PPIs are generally well-tolerated in the elderly population. However, potential safety concerns do exist for long-term and high-dose PPI use. Clinicians should balance the risks and benefits of chronic PPI therapy in older patients and use the lowest effective dose when possible (see Table 2).

**Disclosure**

Justin CY Wu is an invited speaker of the following companies: AstraZeneca, Abbott, Given Imaging, Lundbeck and Takeda. He is also serving in the advisory board of Takeda and Abbott. The authors report no other conflicts of interest in this work.

**References**


